8-K: LeMaitre Vascular Reports Strong Q4, Boosts Dividend & Buyback

LeMaitre Vascular, Inc. announced robust Q4 2025 financial results, including 16% sales growth and 47% operating income growth, alongside a 25% increase in its quarterly dividend and a new $100 million share repurchase program.

Summary

• Q4 2025 sales reached $64.5 million, a 16% increase (15% organic) compared to Q4 2024.
• Gross margin improved to 71.7%, up 240 basis points, driven by higher average selling prices and manufacturing efficiencies.
• Operating income surged 47% to $18.8 million, resulting in an operating margin of 29%.
• Diluted EPS was $0.68, a 39% increase over Q4 2024.
• Cash and short-term marketable securities increased by $16.1 million sequentially to $359.1 million.
• Full year 2025 sales grew 14%, and operating income grew 30%.
• The Board of Directors approved a 25% increase to the quarterly dividend, raising it to $0.25/share.
• A new share repurchase program of up to $100.0 million of common stock was authorized, set to conclude on February 18, 2027.
• Q1 2026 sales guidance is $65.6 million $67.6 million (midpoint: $66.6 million, +11% GAAP, +10% organic).
• Full year 2026 sales guidance is $276 million $284 million (midpoint: $280 million, +12% GAAP, +12% organic).
• Full year 2026 operating income guidance is $75.0 million $80.7 million (midpoint: $77.8 million, +15% GAAP, +21% adjusted).
• Full year 2026 diluted EPS guidance is $2.81 $3.01 (midpoint: $2.91, +16% GAAP, +22% adjusted).

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong financial performance, significant operational leverage, increased shareholder returns, and optimistic forward guidance, indicating robust business health and strategic execution.

Positives

• Strong Q4 2025 sales growth of 16% (15% organic) driven by Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%).
• Significant operating income growth of 47% in Q4 2025, demonstrating strong operational leverage.
• Improved gross margin by 240 basis points to 71.7% due to higher average selling prices and manufacturing efficiencies.
• Diluted EPS increased by 39% to $0.68 in Q4 2025.
• Healthy cash position, increasing sequentially by $16.1 million to $359.1 million.
• Full year 2025 showed strong operating leverage with 14% sales growth and 30% operating income growth.
• Quarterly dividend increased by 25% to $0.25/share, enhancing shareholder returns.
• Authorization of a new $100.0 million share repurchase program, signaling confidence in valuation.
• Positive 2026 guidance projecting continued healthy sales and profit growth (12% sales, 21% adjusted op. income, 22% adjusted EPS).
• Strong international sales growth: EMEA increased 29% and APAC increased 20% in Q4 2025.

Risks

• Ability to maintain historic levels of profit growth.
• Ability to increase the selling prices of products.
• Competition from other medical device companies and alternative medical technologies.
• Ability to source, acquire, and integrate acquisitions.
• Dependence on soleor limited-source suppliers.
• Ability to engage sales call points other than vascular surgeons.
• Disruptions to information technology systems or breaches of information security systems.
• Implementation of a new enterprise resource planning system.
• Ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements.
• Impact of a disruption in manufacturing facilities.
• Ability to navigate the risks inherent in operating internationally.
• Ability to transition to direct sales models in certain international territories.
• Status of regulatory approvals and compliance with regulatory requirements to market and sell products both domestically and internationally.
• Occurrence of litigation relating to product liability, employment matters, intellectual property, contract disputes, and other matters.
• Occurrence of product defects or recalls.
• Ability to service and repurchase debt.
• Dilutive effect of a conversion of debt.
• Ability to navigate executive officer transitions and retain key personnel.
• Ability to protect intellectual property.
• Volatility in the price of common stock.
• Preliminary and unaudited financial results are subject to adjustment.

Future Outlook

The company projects continued healthy sales and profit growth for 2026, with full year sales expected to be between $276 million and $284 million (midpoint $280 million, +12% organic) and adjusted operating income between $75.0 million and $80.7 million (midpoint $77.8 million, +21% adjusted). Adjusted diluted EPS is guided to be between $2.81 and $3.01 (midpoint $2.91, +22% adjusted).

Management Comments

• "International Artegraft growth, higher ASPs and disciplined spending produced 16% Q4 sales growth and 47% op. income growth." George LeMaitre, Chairman/CEO.
• "Full year 2025 showed similar op. leverage: 14% sales growth & 30% op. income growth." George LeMaitre, Chairman/CEO.
• "2026 guidance of $280mm (+12%) in sales and op. income of $77.8mm (+21% adjusted) suggests another year of healthy sales & profit growth." George LeMaitre, Chairman/CEO.

Industry Context

StockSavvy.ai notes that LeMaitre Vascular's strong performance in Q4 2025, particularly in international markets (EMEA +29%, APAC +20%) and key product categories like grafts and valvulotomes, indicates robust demand for peripheral vascular disease treatments. The company's ability to expand gross margins through higher average selling prices and manufacturing efficiencies suggests effective cost management and pricing power within its niche, potentially outperforming competitors facing inflationary pressures.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to increased dividend, share repurchase program, strong financial performance, and positive future outlook, potentially leading to increased stock value and direct returns.
• Employees: Positive impact from a growing and profitable company, potentially leading to job security and opportunities, though no specific employee-related announcements were made.
• Customers: Continued provision of vascular devices, implants, and services for peripheral vascular disease treatment.
• Creditors: Strong financial health and cash position reduce credit risk.

Next Steps

• Payment of the increased quarterly dividend on March 26, 2026, to stockholders of record on March 12, 2026.
• Execution of the share repurchase program, which concludes on February 18, 2027, unless extended.
• Management will conduct a conference call at 5:00pm ET on February 25, 2026, to discuss results and guidance.

Key Dates

Recommendation

The company delivered exceptional Q4 2025 results with robust sales and operating income growth, significantly improved margins, and a strong cash position. The 25% dividend increase and $100 million share repurchase program underscore management's confidence and commitment to shareholder returns. Furthermore, the positive 2026 guidance projects continued healthy growth, suggesting sustained momentum. These factors collectively indicate a strong financial trajectory and attractive investment opportunity.

Keywords

LeMaitre Vascular, LMAT, Q4 2025 results, financial results, dividend increase, share repurchase, vascular devices, medical devices, peripheral vascular disease, earnings, guidance, sales growth, operating income, EPS, gross margin